Testing new MS medicines in people with active relapsing MS
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests different approved “disease-modifying” MS medicines (shots and pills) in adults with relapsing multiple sclerosis that is currently active. It mainly looks at outcomes based on how newly starting—or recently started—treatments are handled for people with recent relapses and mild disability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and able to give informed consent
- You must have a confirmed diagnosis of relapsing multiple sclerosis (RMS)
- Your MS must be “active,” meaning you’ve had relapses recently
- Your disability level must be mild (EDSS about 0 to 2.5 in one group or up to 3.0 in another)
- You must be starting an approved MS medicine, or have started one within the last 14 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine given as a shot under the skin for people with relapsing multiple sclerosis. It aims to see if the medicine is safe and how well it works in reducing MS activity.
This is an observational study (no random treatment) that follows adults with relapsing multiple sclerosis (RMS) who are taking ofatumumab. The study aims to better understand how patients do in real-world care while completing questionnaires and other scheduled check-ins.
This study tests an oral medication, dimethyl fumarate, which is already used for multiple sclerosis. It aims to see how well it controls relapses in people with relapsing forms of MS. If you have had a relapse in the last year, you might be eligible.
This Phase 3 trial tests the safety and effectiveness of a modified treatment plan using ublituximab for relapsing multiple sclerosis. It also studies how the drug behaves in the body and aims to improve disease control while monitoring side effects.
This trial tests a new drug called ublituximab to see if it can reduce flare-ups in children and teens who have relapsing multiple sclerosis. It aims to understand if the treatment is safe and effective for younger patients.
This trial tests if ofatumumab can help people with relapsing multiple sclerosis (RMS) by measuring its effect on nerve damage markers in the blood. It aims to see if the drug is safe and effective for controlling relapses and slowing disease activity.
Hear when a new Relapsing Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.